Navigating and Overcoming Challenges of PSMA-PET Imaging Results Interpretation

Experts share potential solutions to overcome the clinical challenges of using PSMA-PET in practice, including use of reader training programs.

EP: 1.Risk Stratification of Patients with Prostate Cancer

EP: 2.Conventional Imaging for Prostate Cancer

EP: 3.Introduction to PSMA-Targeted PET Imaging

EP: 4.Approved PSMA-PET Imaging Tracer Options for Prostate Cancer

EP: 5.Practical Considerations for Selection of PSMA-PET Tracers

EP: 6.Impact of PSMA-Targeted Imaging Modalities on Management of Prostate Cancer

EP: 7.Overview of Available Clinical Guidelines on PSMA-PET Imaging in Prostate Cancer

EP: 8.Challenges of Implementing PSMA-Targeted PET Imaging in Prostate Cancer

Now Viewing

EP: 9.Navigating and Overcoming Challenges of PSMA-PET Imaging Results Interpretation

EP: 10.Best Practices for Communication: A Multidisciplinary Perspective

EP: 11.Navigating Virtual Tumor Boards for Prostate Cancer PSMA-PET Imaging

EP: 12.Unmet Needs in Imaging for Patients With Prostate Cancer

EP: 13.PSMA-Based Imaging and Theranostics: A Summary of Current Paradigm Shifts and a Look to the Future

EP: 14.Closing Thoughts on the Impact of PSMA-PET Imaging in Prostate Cancer

Related Videos

Related Content

Advertisement

November 21st 2024

FDA accepts sNDA for darolutamide plus ADT in mHSPC

Hannah Clarke

The sNDA is supported by data from the pivotal phase 3 ARANOTE trial.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

November 13th 2024

ECLIPSE trial: 177Lu-PSMA-I&T extends rPFS vs hormone therapy in mCRPC

Hannah Clarke

Final completion of the ECLIPSE trial is anticipated for February 2029.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

November 7th 2024

Phase 1/2 trial of ONCT-534 in mCRPC has been terminated

Hannah Clarke

The decision was based on an interim readout from the trial, which showed that ONCT-534 did not lead to any clinically meaningful improvement of disease.

November 5th 2024

Trial launches of Barrigel rectal spacer for post-prostatectomy radiation therapy

Hannah Clarke

In total, the study plans to enroll 84 adult patients across clinical trial sites in the United States and Australia.

Related Content

Advertisement

November 21st 2024

FDA accepts sNDA for darolutamide plus ADT in mHSPC

Hannah Clarke

The sNDA is supported by data from the pivotal phase 3 ARANOTE trial.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

November 13th 2024

ECLIPSE trial: 177Lu-PSMA-I&T extends rPFS vs hormone therapy in mCRPC

Hannah Clarke

Final completion of the ECLIPSE trial is anticipated for February 2029.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

November 7th 2024

Phase 1/2 trial of ONCT-534 in mCRPC has been terminated

Hannah Clarke

The decision was based on an interim readout from the trial, which showed that ONCT-534 did not lead to any clinically meaningful improvement of disease.

November 5th 2024

Trial launches of Barrigel rectal spacer for post-prostatectomy radiation therapy

Hannah Clarke

In total, the study plans to enroll 84 adult patients across clinical trial sites in the United States and Australia.